AI assistant
FATE THERAPEUTICS INC — Director's Dealing 2016
Jan 14, 2016
34091_dirs_2016-01-14_a2614e52-37d9-40a4-b0d6-51357cbe5344.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2016-01-12
Reporting Person: Wolchko J Scott (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-01-12 | Common Stock | A | 10956 | $0.00 | Acquired | 131979 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-01-12 | Stock option (right to buy) | $2.70 | A | 189600 | Acquired | 2026-01-11 | Common Stock (189600) | Direct |
| 2016-01-12 | Stock option (right to buy) | $2.70 | A | 110400 | Acquired | 2026-01-11 | Common Stock (110400) | Direct |
Footnotes
F1: Represents shares issued pursuant to the Company's 2013 Stock Option and Incentive Plan as a portion of a bonus earned by the reporting person for the fiscal year ended December 31, 2015.
F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on January 1, 2016 such that this option is fully exercisable on December 1, 2019. This option is subject to accelerated vesting in the event of termination of employment under certain circumstances within three months prior to or 18 months following a change of control of the issuer.
F3: Not applicable.
F4: The shares subject to this option shall vest and become exercisable, if at all, in up to three equal installments upon the achievement of certain underlying performance milestones by certain specified dates or will be subject to forfeiture.